120 PRESIDENTIAL WAY,, WOBURN, MA
Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Annual Meeting of Stockholders - Directors Elected: Beth J. Hoffman, Kevin D....
Reports First Quarter 2026 Financial Results and Provides a Business Update
Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for Moderate to Severe Acne Vulgaris
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Patent 11,697,028 To Be Unpatentable
Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Q2
Amended Annual Report
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-1
Amended Registration Statement for Securities
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Definitive Revised Proxy Statement